Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3681 participants.

Also called NCT01854918

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,681 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01854918
  • EudraCT 2012-004357-83
Other papers using this trial's data
  • Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus The American journal of cardiology, 2017-11-01 DOI, PubMed 28844508
  • Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia Journal of clinical lipidology, 2017 DOI, PubMed 29066265

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong SAR China, Hungary, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01854918. Randomized; no masking; primary purpose treatment. Start 2013-04-23 (actual); primary completion 2018-05-31 (actual). Results posted on 2019-06-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
Acronym
OSLER-2
Condition
Hyperlipidemia and Mixed Dyslipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Standard of Care
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01854918
Content hash
35dc86fd66bc4a94bb127a42933b6bd9721ec9583f35155d33566963b59d17d0